Clinical TrialJun 11, 2026, 07:01 AM
C4 Therapeutics Cemsidomide Phase 1 ORR 53% in RRMM
AI Summary
C4 Therapeutics presented positive Phase 1 data for cemsidomide, an IKZF1/3 degrader, in relapsed/refractory multiple myeloma (RRMM) at EHA 2026. At the 100 µg Recommended Phase 2 Dose, cemsidomide achieved a 53% Overall Response Rate, including complete responses and minimal residual disease negative status. The drug demonstrated a differentiated safety profile and was well tolerated, supporting its potential as a foundational therapy for RRMM. The company plans further development, including a Phase 2 trial and a combination study with elranatamab.
Key Highlights
- Cemsidomide achieved a 53% Overall Response Rate (ORR) at the 100 µg RP2D in RRMM patients.
- Responses included complete responses and Minimal Residual Disease (MRD) negative status.
- The drug was well tolerated with minimal discontinuations (0%) and dose reductions (7%) due to safety.
- Median duration of response was 7.9 months, with 7 patients remaining on treatment.
- ORR was 40% at the 75 µg dose level and 36% across all doses evaluated.
- Grade 3/4 neutropenia occurred in 42 patients (58%) but was manageable.
- Data from 73 heavily pretreated patients (median 7 prior lines of therapy).
Price Impact
More from CCCC